Looks like there's something for everyone with the
Post# of 148167
(Total Views: 559)
Posted On: 04/01/2021 7:25:55 AM
Looks like there's something for everyone with the 2 PR's today.
(for the skeptics and pessimists) The new PR's are absolutely horrendous. They think trial enrollment will be expedited because the UK, Canada and Brazil will be enrolling patients...but the PR is horribly written, it says "The half-life of leronlimab is 10 days and with only 2 doses"...well now that its in Brazil they speak spanish and dose means 2 in spanish so is that 4 doses meaning 4x2 or the english version of 4 doses...CLARIFICATION must be given at once!!
(for the eternal cheerleaders)The conference call is on Tuesday instead of Monday which means something HUGE must be happening because the normal day of the last 2 calls was Monday. It certainly would have nothing to do with Tuesday being the one day they were all free from other obligations to have a call.
(for the bashers lurking) I noticed HIV BLA was not mentioned on the CC PR. Must have given up on that indication altogether.
(for the skeptics and pessimists) The new PR's are absolutely horrendous. They think trial enrollment will be expedited because the UK, Canada and Brazil will be enrolling patients...but the PR is horribly written, it says "The half-life of leronlimab is 10 days and with only 2 doses"...well now that its in Brazil they speak spanish and dose means 2 in spanish so is that 4 doses meaning 4x2 or the english version of 4 doses...CLARIFICATION must be given at once!!
(for the eternal cheerleaders)The conference call is on Tuesday instead of Monday which means something HUGE must be happening because the normal day of the last 2 calls was Monday. It certainly would have nothing to do with Tuesday being the one day they were all free from other obligations to have a call.
(for the bashers lurking) I noticed HIV BLA was not mentioned on the CC PR. Must have given up on that indication altogether.
(6)
(3)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼